Author

William Couldwell

University of Utah

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Abigail G ParrishiD· 1 shared David Austin NixiD· 1 shared David L. GillespieiD· 1 shared Dylan J Keiser· 1 shared Frank SzulzewskyiD· 1 shared Howard ColmaniD· 1 shared Meghan S Buddy· 1 shared Missia Kohler-Skinner· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abigail G ParrishORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Comprehensive analysis of TEAD inhibition in meningioma identifies MEK and mTOR inhibition as effective combination therapies against resistant lines.

Dylan J Keiser, Meghan S Buddy, Solmaz Mojarad-Jabali, Qing Li, Missia Kohler-Skinner, Abigail G Parrish, David L. Gillespie, David Austin Nix, Sheri L. Holmen, Howard Colman, William Couldwell, Randy L. Jensen, Frank Szulzewsky

This study identifies TEAD inhibition as a therapeutic target in meningioma and shows that combining MEK and mTOR inhibition overcomes resistance in resistant lines.

bioRxiv · Mar 25, 2026 · PreprintCancer Biology